Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness

JAMA

Volumn 285, Issue 24, 2001, Pages 3107-3115

  Goldie, Sue J ^a   Kuhn, Louise ^c   Denny, Lynette ^b   Pollack, Amy ^d   Wright, Thomas C ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Columbia University ^*  (United States)

^d ENGENDERHEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CYTODIAGNOSIS; DIAGNOSTIC TEST; HEALTH CARE COST; HEALTH CARE POLICY; HIGH RISK POPULATION; MATHEMATICAL MODEL; PRIORITY JOURNAL; RESOURCE MANAGEMENT; SCREENING; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0035958252     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.24.3107     Document Type: Article

References (79)

1. Estimates of the worldwide mortality from 25 cancers in 1990
2. Estimates of the worldwide incidence of 25 major cancers in 1990
3. Detection of cervical intraepithelial neoplasia in developing countries
4. Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa
5. AIDS-related cancers in Africa
6. IARC monographs on the evaluation of carcinogenic risks to humans
7. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer
8. Visual inspection of the uteri ne cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors
9. Visual inspection with acetic acid for cervical-cancer screening
10. HPV-based cervical cancer screening in a population at high risk for HIV infection
11. Evaluation of alternative methods of cervical cancer screening for resource-poor settings
12. Human papillomavirus testing as a screening tool for cervical cancer
13. Natural history of cervicovaginal papillomavirus infection in young women
14. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia
15. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease
16. Human papillomavirus infection in women infected with the human immunodeficiency virus
17. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening
18. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women
19. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities
20. Persistence of type-specific human papillomavirus infection among cytologically normal women
21. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears
22. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer
23. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica
24. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women
25. Cryosurgery for cervical intraepithelial neoplasia: 10-year follow-up
26. Cryosurgery in the management of cervical intraepithelial neoplasia
27. Outcome of cryosurgery for cervical intraepithelial neoplasia in a developing country
28. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix
29. A systematic review of the role of human papillomavirus testing within a cervical screening programme
30. Natural history of dysplasia of the uterine cervix
31. Natural history of cervical intraepithelial neoplasia: A critical review
32. Strategies for global control of cervical cancer
33. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis
34. Evaluating cervical cancer screening programmes for developing countries
35. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda system
36. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to human papillomavirus infection
37. Can papilloma virus testing be used to improve cervical cancer screening?
38. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings
39. Meta-analysis of Pap test accuracy
40. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities
41. Early detection of cervical cancer by visual inspection
42. HPV testing in primary screening of older women
43. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions
44. Screening for cervical neoplasia by self-assessment for human papillomavirus DNA
45. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human-papillomavirus testing to detect high-grade squamous intraepithelial lesions
46. Collection devices for human papillomavirus
47. Two-stage cervical cancer screening
48. An overview of cancer survival in developing countries
49. Carcinoma of the cervix in the African setting
50. Evaluation of screening for cervical cancer in Sweden
51. Statistical analysis of the stages of HIV infection using a Markov model
52. Survival from early, intermediate, and late stages of HIV infection
53. The cost-effectiveness of preventing AIDS-related complications
54. The 1988 Bethesda System for reporting cervical/ vaginal cytological diagnoses
55. Incidence of cervical squamous intraepithelial lesions in HIV-infected women
56. Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus
57. FIGO staging of gynecologic cancer
58. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women
59. Assessing the effectiveness of health interventions for cost-effectiveness analysis
60. Trends in cervical cancer mortality in South Africa
61. Natural history and spectrum of disease in adults with HIV/AIDS in Africa
62. Care and costs of advanced cervical cancer
63. Benchmarks for health expenditures, services and outcomes in Africa during the 1990's
64. Histologically diagnosed cancers in South Africa, 1988
65. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania